News from daiichi sankyo A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 19, 2018, 08:35 ET Daiichi Sankyo Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

Daiichi Sankyo (JP: 4568.T, OTC Pink: DSNKY), based in Tokyo, Japan, focused on the pharmaceutical business, today announced that the November 15 presentation from Daiichi Sankyo, Senior Director, IR ...


Nov 08, 2018, 08:35 ET Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15, 2018

Daiichi Sankyo (Japan: 4568.T, OTC: DSNKY) based in Tokyo, Japan, and focused on pharmaceutical business, today announced that Daiichi Sankyo, Senior Director, IR group Mr. Junichi Onuma will present ...


Jun 27, 2016, 08:00 ET Daiichi Sankyo Enters Into Agreement with Servier Canada For Factor Xa Inhibitor Edoxaban

Daiichi Sankyo Co., Limited (hereafter, Daiichi Sankyo) (TSE: 4568) today announced that it has entered into an agreement with Servier Canada (Laval, Quebec) whereby Servier Canada will market the...


Dec 08, 2014, 07:09 ET Daiichi Sankyo Launches New Formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA® 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval...


Mar 24, 2014, 07:01 ET Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral

- Subgroup analyses of East Asian populations from two phase 3 studies, ENGAGE AF-TIMI 48 and Hokusai-VTE, showed consistent results compared to the global study populations from these...


Jan 07, 2014, 11:10 ET Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO and ...


Dec 09, 2013, 08:05 ET Phase 3 Data Show Daiichi Sankyo's Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a

- VTE patients with cancer treated with once-daily edoxaban had a numerically lower incidence of recurrent VTE and a 36% lower risk of clinically relevant bleeding compared to warfarin in a subgroup...


Nov 19, 2013, 11:50 ET Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared

- Once-daily edoxaban, evaluated in two treatment arms (60 mg and 30 mg), achieved the primary endpoint of non-inferior efficacy versus warfarin in the prevention of stroke or systemic embolism -...


Aug 26, 2012, 02:01 ET Daiichi Sankyo and Lilly Announce TRILOGY ACS Results Regarding Effient® (Prasugrel) in Acute Coronary Syndrome UA/NSTEMI Patients to be Managed

Study did not meet primary objective of demonstrating prasugrel superiority over clopidogrel in this patient population INDIANAPOLIS and TOKYO, Aug. 26, 2012 /CNW/ - Daiichi Sankyo Company, Limited...